The US Federal Trade Commission (FTC) has given Germany’s Fresenius Medical Care and US home dialysis equipment maker NxStage Medical antitrust approval for their merger, the agency said on Tuesday, February 19.
To win approval for the US$2 billion deal, the companies agreed to sell NxStage’s bloodline tubing set business, the agency stated. Fresenius and NxStage together dominate the market for the single-use plastic tubes used during dialysis, the agency stated.
The five FTC commissioners split along party lines in voting on whether to approve the merger. The three Republicans—Joseph Simons, Noah Phillips, and Christine Wilson—voted “yes,” while Democrats Rohit Chopra and Rebecca Slaughter dissented.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
CVS Health Explores Potential Breakup Amid Investor Pressure: Report
Oct 3, 2024 by
CPI
DirecTV Acquires Dish TV, Creating 20 Million-Subscriber Powerhouse
Oct 3, 2024 by
CPI
South Korea Fines Kakao Mobility $54.8 Million for Anti-Competitive Practices
Oct 3, 2024 by
CPI
Google Offers Settlement in India’s Antitrust Case Regarding Smart TVs
Oct 3, 2024 by
CPI
Attorney Challenges NCAA’s $2.78 Billion Settlement in Landmark Antitrust Cases
Oct 3, 2024 by
nhoch@pymnts.com
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh